Akronym	Bezeichnung	Phase	Indikation	Beschreibung	Rekrutierung
IPF STUDIEN					
ISABELA 1 &2	GLPG1690-CL-304	III	Idiopathische Lungenfibrose	A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.	**Aktiv**
Juniper	ND-L02s-0201-005	II	Idiopathische Lungenfibrose	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	**Aktiv**
VAY736 Novartis	CVAY736X2207	II	Idiopathische Lungenfibrose	A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis	**Aktiv**
ZEPHYRUS	FibroGen FGCL-3019-091	III	Idiopathische Lungenfibrose	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	**In Vorbereitung**
Respivant	RVT1601-CC-04	IIb	Idiopathische Lungenfibrose **Behandlung des Hustens**	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	**Abgebrochen**
Celgene	CC-90001-IPF-001	II	Idiopathische Lungenfibrose	A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, multicenter Study, with an 80 week active Treatment Extension, to evaluate the efficacy and safety of CC-90001 in Subjects with IPF.	**Aktiv**

BI 1305-0013	1305-0013	II	Idiopathische Lungenfibrose	A randomized, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 18 mg taken orally b.i.d.	**In Vorbereitung**
Pliant	PLN-74809-IPF-202	IIa	Idiopathische Lungenfibrose	A randomized, double-blind dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF).	**In Vorbereitung**
BMS	IM027-040	II	Idiopathische Lungenfibrose	A Multicenter, randomized, double-blind, placebo-controlled, phase 2 study of the Efficacy and Safety and Tolerability of BMS-986278 in Participants with pulmonary Fibrosis.	**In Vorbereitung**
Galactic	Galactic-1	IIb	Idiopathische Lungenfibrose	A randomized, double-blind,multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks.	**In Vorbereitung**
Nicht-IPF STUDIEN					
INBUILD-ON	1199.248	III	PF-ILD	An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)	**Rekrutierung beendet**
Alveolar Proteinose STUDIEN					
IMPALA	IMPALA MOL PAP 202 Extension	III	Alveolar Proteinose	An open-label,non-controlled, multicentre trial of inhaled Molgramotism in autoimmune pulmonary alveolar proteinosis patients	**Rekrutierung beendet**
IMPALA 2	IMPALA MOL PAP	III	Alveolar	An open-label,non-controlled, multicentre trial of inhaled Molgramotism in autoimmune pulmonary alveolar proteinosis	**In Vorbereitung**

			Proteinose	patients	
Sarkoidose STUDIEN					
Novartis	CCMK389X2201	II	Sarkoidose	A subject and investigator blinded, randomized, placebocontrolled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis.	**Aktiv**